Welcome to LookChem.com Sign In|Join Free

CAS

  • or

88950-64-5

Post Buying Request

88950-64-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

88950-64-5 Usage

Chemical Properties

White crystalline powder

Uses

1-(Boc-amino)cyclopropanecarboxylic Acid is used as a reagent in the synthesis of pyrrolotriazinone derivatives as therapeutic PI3K inhibitors. Also used as a reagent in the synthesis of ether, carbamate and ester derivatives of adarotene as potential antitumor agents.

Check Digit Verification of cas no

The CAS Registry Mumber 88950-64-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,8,9,5 and 0 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 88950-64:
(7*8)+(6*8)+(5*9)+(4*5)+(3*0)+(2*6)+(1*4)=185
185 % 10 = 5
So 88950-64-5 is a valid CAS Registry Number.

88950-64-5 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H61992)  1-(Boc-amino)cyclopropanecarboxylic acid, 98%   

  • 88950-64-5

  • 250mg

  • 819.0CNY

  • Detail
  • Alfa Aesar

  • (H61992)  1-(Boc-amino)cyclopropanecarboxylic acid, 98%   

  • 88950-64-5

  • 1g

  • 2950.0CNY

  • Detail
  • Aldrich

  • (39977)  1-(Boc-amino)cyclopropanecarboxylicacid  ≥98.0% (TLC)

  • 88950-64-5

  • 39977-1G-F

  • 4,502.16CNY

  • Detail

88950-64-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(Boc-amino)cyclopropanecarboxylic acid

1.2 Other means of identification

Product number -
Other names 1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopropane-1-carboxylic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:88950-64-5 SDS

88950-64-5Relevant articles and documents

SUBSTITUTED TRIAZINONES AS THYROID HORMONE RECEPTOR AGONISTS

-

Paragraph 00269-00270, (2021/07/24)

The application relates to a compound of Formula (I') or (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I') or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.

Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1

Maben, Zachary,Arya, Richa,Rane, Digamber,An, W. Frank,Metkar, Shailesh,Hickey, Marc,Bender, Samantha,Ali, Akbar,Nguyen, Tina T.,Evnouchidou, Irini,Schilling, Roger,Stratikos, Efstratios,Golden, Jennifer,Stern, Lawrence J.

, p. 103 - 121 (2020/02/20)

ERAP1 is an endoplasmic reticulum-resident zinc aminopeptidase that plays an important role in the immune system by trimming peptides for loading onto major histocompatibility complex proteins. Here, we report discovery of the first inhibitors selective for ERAP1 over its paralogues ERAP2 and IRAP. Compound 1 (N-(N-(2-(1H-indol-3-yl)ethyl)carbamimidoyl)-2,5-difluorobenzenesulfonamide) and compound 2 (1-(1-(4-acetylpiperazine-1-carbonyl)cyclohexyl)-3-(p-tolyl)urea) are competitive inhibitors of ERAP1 aminopeptidase activity. Compound 3 (4-methoxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid) allosterically activates ERAP1's hydrolysis of fluorogenic and chromogenic amino acid substrates but competitively inhibits its activity toward a nonamer peptide representative of physiological substrates. Compounds 2 and 3 inhibit antigen presentation in a cellular assay. Compound 3 displays higher potency for an ERAP1 variant associated with increased risk of autoimmune disease. These inhibitors provide mechanistic insights into the determinants of specificity for ERAP1, ERAP2, and IRAP and offer a new therapeutic approach of specifically inhibiting ERAP1 activity in vivo.

Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicines

-

Paragraph 0373; 0374; 0375; 0376, (2018/09/08)

The present invention relates to an amine compound for inhibiting SSAO/VAP-1 and application thereof in medicines. In particular, the present invention relates to an amine compound for inhibiting a semicarbazide-sensitive oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, or a pharmaceutically acceptable salt thereof, a stereoisomer or an/a E/Z isomer, further relates to a pharmaceutical composition containing the amine compound. The invention further relates to the application of the amine compound and the pharmaceutical composition in manufacture of the medicines for treatment of inflammation, inflammation-related diseases and immune diseases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 88950-64-5